The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN
Open accessAbstract
Background and Aims: The growing use of glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes mellitus (DM2) and obesity necessitates studies about their use in patients with inflammatory bowel diseases (IBD). Methods: Data on patients with DM2 were retrieved from an Israeli nationwide cohort of patients with IBD (epi-IIRN), recording GLP-1 analog exposure for at least 6 months. The primary outcome was poor disease outcomes (ie, composite of steroid dependence, initiation of advanced IBD therapy, hospitalization, surgery, or death). Cox proportional hazard models with time-varying covariables were used to assess the impact of GLP-1 use on outcomes during follow-up. Results: We included 3737 patients (24 338 patient-years) with IBD and DM2 [50.4% ulcerative colitis (UC)], of whom 633 were treated with GLP-1 analogs. Accounting for demographics IBD/DM2 related variables, medication use, and laboratory measurements, GLP-1 analog use was associated with reduced composite outcome in the full cohort (adjusted hazard ratio [aHR] 0.74, 95% confidence interval [CI] 0.62-0.89) and in each subtype [UC (aHR 0.71, 95% CI 0.52-0.96) and Crohn’s disease (aHR 0.78, 95% CI 0.62-0.99)]. Similar trends were seen in multivariate analyses of each individual outcome, although only hospitalization was significant (aHR 0.74, 95% CI 0.61-0.91). The protective effect of GLP-1 analogs was seen in patients with obesity (aHR 0.61, 95% CI 0.50-0.77), but not in non-obese (aHR 0.94, 95% CI 0.67-1.31). Conclusions: GLP-1 analogs are associated with improved outcomes in IBD, specifically in patients with obesity. The mechanisms of these effects require further investigation as well as their role in patients without DM2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Retrospective cohort studies suggest that the use of GLP-1 medicines is associated with improved inflammatory bowel disease outcomes in people with T2D.
“Retrospective cohort studies suggest that the use of GLP-1 medicines is associated with improved inflammatory bowel disease outcomes in people with T2D (83, 84).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Obesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Obesity and C ‐reactive protein in various populations: a systematic review and meta‐analysis
Choi, J., Joseph, L., & Pilote, L. (2012) · Obesity Reviews · doi:10.1111/obr.12003 · Cited by 657
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
Singh, S., Dulai, P. S., Zarrinpar, A., Ramamoorthy, S. L., & Sandborn, W. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.181 · Cited by 456
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Relation of C-Reactive Protein to Abdominal Adiposity
Brooks, G. C., Blaha, M. J., & Blumenthal, R. S. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.02.017 · Cited by 255
The Impact of Increased Body Mass Index on the Clinical Course of Crohn’s Disease
Hass, D. J., Brensinger, C. M., Lewis, J. D., & Lichtenstein, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.015 · Cited by 213
Suibhne, T. N., Raftery, T. C., McMahon, O., Walsh, C., O'Morain, C. A., & OʼSullivan, M. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.09.009 · Cited by 160
Inflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study
Jess, T., Jensen, B. W., Andersson, M., Villumsen, M., & Allin, K. H. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.052 · Cited by 113
Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Narula, N., Chang, N. H., Mohammad, D., Wong, E. C. L., Ananthakrishnan, A. N., Chan, S. S. M., Carbonnel, F., & Meyer, A. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.012 · Cited by 112
GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000847 · Cited by 111
GLP-1 based therapies and disease course of inflammatory bowel disease
Villumsen, M., Schelde, A. B., Jimenez-Solem, E., Jess, T., & Allin, K. H. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100979 · Cited by 97
Causey, M. W., Johnson, E. K., Miller, S., Martin, M. J., Maykel, J. A., & Steele, S. R. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182342ccb · Cited by 91
Jain, A., Nguyen, N. H., Proudfoot, J. A., Martin, C. F., Sandborn, W. J., Kappelman, M. D., Long, M. D., & Singh, S. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000197 · Cited by 90
Ding, Z., Wu, X. ‐., Remer, E. M., Lian, L., Stocchi, L., Li, Y., McCullough, A. J., Remzi, F. H., & Shen, B. (2015) · Colorectal Disease · doi:10.1111/codi.13128 · Cited by 86
Yarur, A. J., Bruss, A., Moosreiner, A., Beniwal-Patel, P. M., Núñez, L., Berens, B. E., Colombel, J., Targan, S. R., Fox, C., Melmed, G., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.036 · Cited by 77
Friedman, M. Y., Leventer‐Roberts, M., Rosenblum, J., Zigman, N., Goren, I., Mourad, V., Lederman, N., Cohen, N., Matz, E., Dushnitzky, D., et al. (2018) · Clinical Epidemiology · doi:10.2147/clep.s151339 · Cited by 76
Self-citationHunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65
Jiang, K., Chen, B., Lou, D., Zhang, M., Shi, Y., Dai, W., Shen, J., Zhou, B., & Hu, J. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04190-y · Cited by 59
The alleviating effect and mechanism of GLP-1 on ulcerative colitis
Wang, W., Zhang, C., Zhang, H., Li, L., Fan, T., & Jin, Z. (2023) · Aging · doi:10.18632/aging.204953 · Cited by 54
Greuter, T., Porchet, F., Neto, M. B. B., Rossel, J., Biedermann, L., Schreiner, P., Scharl, M. M., Schoepfer, A. M., Safroneeva, E., Straumann, A., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620954556 · Cited by 51
Desai, A., Petrov, J. C., Hashash, J. G., Patel, H. D., Brahmbhatt, B. S., Kochhar, G. S., & Farraye, F. A. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18138 · Cited by 42
Johnson, A. M., Harmsen, W. S., Aniwan, S., Tremaine, W. J., Dayyeh, B. K. A., & Loftus, E. V. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab097 · Cited by 36
Desai, A., Khataniar, H., Hashash, J. G., Farraye, F. A., Regueiro, M. D., & Kochhar, G. S. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae090 · Cited by 32
Elangovan, A., Shah, R., Ali, S. M. J., Katz, J., & Cooper, G. S. (2023) · Crohn s & Colitis 360 · doi:10.1093/crocol/otad007 · Cited by 24
Jeffrey, L. O. (2019) · Clinical Medical Reviews and Case Reports · doi:10.23937/2378-3656/1410281 · Cited by 17
Sodihardjo, F., van Dijk, L., Wensing, M., Smet, P. A. G. M. D., & Teichert, M. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2149-3 · Cited by 15
Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease
Belinchón, C. R., Martínez-Lozano, H., Serrano‐Moreno, C., Castillo, D. H., Chicharro, P. L., Ocampo, P. F., Marín‐Jiménez, I., Lesmes, I. B., & Menchen, L. A. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10305/2024 · Cited by 15
Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data
Fontanet, C. P., Choudhry, N. K., Isaac, T., Sequist, T. D., Gopalakrishnan, C., Gagne, J. J., Jackevicius, C. A., Fischer, M. A., Solomon, D. H., & Lauffenburger, J. C. (2021) · Health Services Research · doi:10.1111/1475-6773.13714 · Cited by 12
Flagged first, then by citations
Cited by
Sorted by citations
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“Retrospective cohort studies suggest that the use of GLP-1 medicines is associated with improved inflammatory bowel disease outcomes in people with T2D (83, 84).”
Clarke, L. M., Pasam, R. T., Falahee, B. E., Jirapinyo, P., Allegretti, J. R., & Kelly, C. R. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08964-6 · Cited by 25
Thin, L. W. Y., & Teh, W. L. (2025) · Biomedicines · doi:10.3390/biomedicines13051128 · Cited by 17
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 18
Deza, D. C., García‐López, S., Monterde, V. B., Cuadro, C. P., Caballero, C. Y., & Arbonés-Mainar, J. M. (2025) · Biomolecules · doi:10.3390/biom15081185 · Cited by 20
Bayoumy, A. B., Clarke, L. M., Deepak, P., Desai, A., Sehgal, P., Gorelik, Y., Bar‐Yoseph, H., Villumsen, M., Mulder, C. J. J., Stenvers, D. J., et al. (2025) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf181 · Cited by 14
Self-citationMousavi, S., Bieber, K., Zirpel, H., Vorobyev, A., Olbrich, H., Papara, C., Luca, D. A. D., Thaçi, D., Schmidt, E., Riemekasten, G., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1516433 · Cited by 12
Impact of GLP-1 analogues on immune-mediated inflammatory diseases: A systematic review
Birda, C. L., Ibrahim, F., Chatterjee, A., Jena, A., Sharma, V., & Sebastian, S. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103936 · Cited by 12
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis
Mohan, N., Srivastava, S. K., Schulgit, M. J., Nowacki, A. S., Kaelber, D. C., & Sharma, S. K. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2822 · Cited by 11
Application of zein nanoparticles for the treatment of inflammatory bowel diseases
Gagliardi, A., Valle, M. D., Espuelas, S., Irache, J. M., & Cosco, D. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2527693 · Cited by 10
Relevance of Glucagon-Like Peptide 1 (GLP-1) in Inflammatory Bowel Diseases: A Narrative Review
Gravina, A. G., Pellegrino, R., Izzo, M., Costanzo, I. D., Imperio, G., Landa, F., Tambaro, A., & Federico, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050383 · Cited by 10
Maracle, B., Quan, S., Hamilton, P., Shaikh, A., Hazra, D., Lorenzetti, D., Gold, S. L., Raman, M., & St‐Pierre, J. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70485 · Cited by 8
Stenberg, E., Everhov, A. H., Söderling, J. K., Ottosson, J., Osooli, M., SWIBREG study group, Myrelid, P., Strid, H., Nordenvall, C. A. M., Hedin, C. R. H., et al. (2025) · BJS Open · doi:10.1093/bjsopen/zraf086 · Cited by 6
The ‘Obesity First’ approach: Redefining the future of healthcare
Mulder, C. J. J., Bayoumy, A. B., & Ansari, A. R. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01882-5 · Cited by 7
Solitano, V., Peyrin‐Biroulet, L., Vermeire, S., Dubinsky, M. C., Siegmund, B., Mosig, R., Cataldi, F. A., Derluyn, L., Danese, S., & Verstockt, B. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf315 · Cited by 4
Shirmard, F. O., Pourfaraji, S. M., Omouri‐Kharashtomi, M., & Amani, A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04496-5 · Cited by 3
GLP-1 receptor agonists in asthma: targeting metabolic-inflammatory crossroads
O’Brien, H., Franciosi, A. N., & Butler, M. W. (2026) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001249 · Cited by 3
Birda, C. L., & Sebastian, S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01854-9 · Cited by 2
Ilyés, T., Grama, P., Gheorghe, S. R., Anton, V., Silaghi, C. N., & Craciun, A. M. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16030032 · Cited by 2
Aksan, F., Abboud, A., Tanrıverdi, L. H., Aroniadis, O. C., & Monzur, F. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04745-0 · Cited by 3
Lee, J. J., Bajgain, P., & Lightner, A. L. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1790420 · Cited by 3
Troshina, E. A., Antsiferov, M. B., As, A., Bakulin, I. G., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2026) · Problems of Endocrinology · doi:10.14341/probl13784 · Cited by 2
Kherad, O., Martel, M., Afif, W., Bessissow, T., Barkun, A. N., & Restellini, S. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2026-103640 · Cited by 2
Pugliese, N., Spertino, M., Mercurio, M., Ciardullo, S., Perseghin, G., Hassan, C., Vettor, R., Petta, S., & Aghemo, A. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.018 · Cited by 2
Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
St‐Pierre, J., Maracle, B., & Seow, C. H. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70538 · Cited by 1
Mesenteric adipose tissue: from protective gatekeeper to driver of inflammatory bowel disease
Gliniak, C. M. (2026) · Immunometabolism · doi:10.1097/in9.0000000000000081 · Cited by 1
Omar, T., Weidinger, C., & Siegmund, B. (2026) · European Journal of Immunology · doi:10.1002/eji.70222 · Cited by 3
Bayoumy, A. B., Clarke, L. M., Deepak, P., Desa, A., Sehgal, P., Gorelik, Y., Bar‐Yoseph, H., Mulder, C. J. J., Stenvers, D. J., Tushuizen, M. E., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5246533 · Cited by 1
Self-citationSacoor, Y., & Pillay, S. (2025) · South African journal of gastroenterology and hepatology. · doi:10.36303/sajgh.3363
Saadeh, M., Chandar, A. K., Baskin, R. G., Katz, J., Cominelli, F., Mansoor, E., Regueiro, M., & Nguyen, V. Q. C. (2026) · GastroHep · doi:10.1155/ygh2/2239686
Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis
Alqinai, B., Adeniran, O. F., Adekolu, A. A., & Gayam, S. (2026) · ACG Case Reports Journal · doi:10.14309/crj.0000000000002070
Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review
Desai, A., Habib, H., Wahbeh, L., & Farraye, F. A. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101023
Yeh, K.-H., Ahuja, D., Patel, S. B., Xu, R., Park, S.-K., Gold, S. L., Ramos, G. P., Malik, T., Kaur, M., Bering, J., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.06.008 · Cited by 1
Çağatay, C., Keskin, M. K., & Gülten, M. (2026) · Research Square · doi:10.21203/rs.3.rs-10075921/v1
Beniwal-Patel, P. M., Samaan, S., Abreu, M. T., Deepak, P., & Yarur, A. J. (2026) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izag151 · Cited by 1
Fernando, S., Zhao, J., Josloff, K., Zubair, N., Desai, A., Shivashankar, R., Kozuch, P. L., Choudhary, C., Lichtenstein, G. R., & Sehgal, P. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1864456
Wie das metabolische Syndrom den Verlauf beeinflusst
Stange, E. F. (2026) · Gastro-News · doi:10.1007/s15036-026-4079-y
O'Brien, H., Byrne, A. J., Franciosi, A., & Butler, M. W. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00380-z
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Brogaard, E., Nielsen, V. W., Pedersen, N. H., & Thomsen, S. F. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2738341
Abuhussein, E., Yamaguchi, Y., Singh, D. K., Orahovats, C. E., Nishiyama, K., Tsuboi, K., & Huang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1970634
Metadata
- Authors
- Gorelik, Y., Ghersin, I., Lujan, R., Shlon, D., Loewenberg Weisband, Y., Ben-Tov, A., Matz, E., Zacay, G., Dotan, I., Turner, D., & Bar-Yoseph, H.
- Affiliations
- Rambam Health Care Campus (IL)
- Hebrew University of Jerusalem (IL)
- Innovation Division, Clalit Research Institute , Tel Aviv ,
- Medical Informatics, Maccabi Health Services , Tel Aviv ,
- Leumit Health Services , Tel-Aviv ,
- Tel Aviv University (IL)
- Rambam Health Care Campus Department of Gastroenterology, , Haifa ,
- ORCID
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-10-23
- Volume
- 19
- Issue
- 4
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W4403664903
- Cited by
- 41
- References
- 31
- Citations by year
- 2026: 20 · 2025: 21
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Crohn s and Colitis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leona M. and Harry B. Helmsley Charitable Trust (G-2203-05900)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- GLP-1 analogues, inflammatory bowel disease
- MeSH terms
- Adult, Aged, Colitis, Ulcerative, Crohn Disease, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Hypoglycemic Agents, Israel, Male, Middle Aged, Obesity, Inflammatory Bowel Diseases, Proportional Hazards Models, Treatment Outcome, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
